Daiichi Sankyo Begins Phase 3 Study For Edoxaban
Daiichi Sankyo announced that it has initiated enrollment of patients into the multinational Phase III study ENSURE-AF evaluating the safety and efficacy of edoxaban against enoxaparin and warfarin. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 4, 2014 Category: Pharmaceuticals Source Type: news

FDA Underlines Risk of Spinal Procedures on LMW HeparinsFDA Underlines Risk of Spinal Procedures on LMW Heparins
The FDA announced new recommendations aimed at reducing the risk of spinal bleeding with epidural and lumbar puncture procedures among patients taking enoxaparin and other low-molecular-weight heparins. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA updates warning on Sanofi's blood thinner Lovenox
(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding and potential paralysis. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Bleed Risk Falls with Bivalirudin en Route to PCI for STEMIBleed Risk Falls with Bivalirudin en Route to PCI for STEMI
Some will recognize shades of HORIZONS AMI: the gains came from bivalirudin vs heparin or enoxaparin for STEMI, initiated in EUROMAX while patients were in an ambulance en route to a PCI center. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
The novel anticoagulant can now be considered for both acute and extended treatment of VTE, with a lower risk of major bleeding than standard treatment with enoxaparin and warfarin. (Source: Consultant Live)
Source: Consultant Live - July 18, 2013 Category: Primary Care Source Type: news

Apixaban vs Standard Anticoagulation in Acute VTEApixaban vs Standard Anticoagulation in Acute VTE
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

AMPLIFY: Apixaban in acute VTE as effective but safer than standard anticoagulation
The oral factor Xa inhibitor was noninferior for efficacy and led to a 69% drop in major bleeding complications in patients with acute deep vein thrombosis or pulmonary embolism, compared with enoxaparin followed by warfarin. (Source: theHeart.org)
Source: theHeart.org - July 1, 2013 Category: Cardiology Source Type: news

STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

RCT: Rivaroxaban for thromboprophylaxis in acutely ill medical patients (MAGELLAN)
Source: N Engl J Med Area: News RCTs of hospitalised patients at increased risk for venous thromboembolism (VTE) have shown the benefits of administering anticoagulant agents for up to 14 days. There is some evidence that the risk of VTE in acutely ill medical patients persists after hospital discharge, but no studies have supported the routine use of extended thromboprophylaxis.   Rivaroxaban is an oral, direct factor Xa inhibitor that is used for the prevention of VTE after elective hip-replacement or knee-replacement surgery in adults. The 'Multicenter, Randomised, Parallel Group Efficacy and Safety Study for...
Source: NeLM - Cardiovascular Medicine - February 7, 2013 Category: Cardiology Source Type: news

Rivaroxaban Noninferior to Enoxaparin in VTE Prophylaxis, but at a Cost
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 7, 2013 Category: Primary Care Tags: Medical News Source Type: news

Rivaroxaban Reduces VTE Risk in Acutely Ill PatientsRivaroxaban Reduces VTE Risk in Acutely Ill Patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

MAGELLAN published: Rivaroxaban reduces VTE risk in acutely ill patients
Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. (Source: theHeart.org)
Source: theHeart.org - February 6, 2013 Category: Cardiology Source Type: news

VTE Risk Falls, Bleeds Rise with Longer Prophylaxis (CME/CE)
(MedPage Today) -- Extended treatment with rivaroxaban (Xarelto) resulted in better protection for patients at risk of venous thromboembolism than those treated with a standard course of enoxaparin, a large randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2013 Category: Cardiology Source Type: news